HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics (NASDAQ:AXSM) had its price objective lifted by investment analysts at HC Wainwright from $190.00 to $200.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 45.19% from the stock’s previous close. HC Wainwright also issued estimates for Axsome Therapeutics’ Q1 2026 earnings at $0.11 EPS and FY2026 earnings at $7.52 EPS.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners increased their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research report on Wednesday. Bank of America boosted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Mizuho upped their target price on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 11th. Finally, Truist Financial lifted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $157.64.

Axsome Therapeutics Stock Up 6.7 %

NASDAQ AXSM opened at $137.75 on Thursday. The company has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22. The company has a 50 day moving average of $101.29 and a 200-day moving average of $94.84.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, equities research analysts expect that Axsome Therapeutics will post -2.26 earnings per share for the current fiscal year.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. TFG Asset Management GP Ltd bought a new position in shares of Axsome Therapeutics during the fourth quarter worth about $3,490,000. GF Fund Management CO. LTD. acquired a new stake in Axsome Therapeutics during the 4th quarter valued at approximately $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Axsome Therapeutics during the 4th quarter worth approximately $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock worth $4,877,000 after purchasing an additional 9,928 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of Axsome Therapeutics by 36.8% in the 4th quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock valued at $34,558,000 after purchasing an additional 109,872 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.